Inhibitors of dipeptidyl peptidase IV: A novel approach for the prevention and treatment of type 2 diabetes?

Expert Opinion on Investigational Drugs

Volumn 13, Issue 9, 2004, Pages 1091-1102

  Deacon, Carolyn F ^a   Ahrén, Bo ^b   Holst, Jens J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Dipeptidyl peptidase; Enteroinsular axis; Enzyme inhibitor; Glucagon like peptide 1; Glucose dependent insulinotropic polypeptide; Incretin; Oral antidiabetic agent

Indexed keywords

1 [4 METHYL 1 (2 PYRIMIDINYL) 4 PIPERIDYLAMINOACETYL] 2 PYRROLIDINECARBONITRILE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; AMINO ACID; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; GLUCOSE DEPENDENT INSULINOTROPIC POLYEPTIDE; HYDROLASE INHIBITOR; INSULIN; ISOLEUCINE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PYRROLIDINE DERIVATIVE; SITAGLIPTIN; SULFONYLUREA; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG; VALINE; VILDAGLIPTIN;

AMINO TERMINAL SEQUENCE; BODY WEIGHT DISORDER; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG DESIGN; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUSTRY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME DEGRADATION; ENZYME INHIBITION; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HORMONE RELEASE; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; MEDICAL SPECIALIST; METABOLITE; MOLECULAR DYNAMICS; MOLECULAR WEIGHT; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL EDEMA; PRURITUS; REVIEW; RHINOPHARYNGITIS; WEIGHT GAIN;

ANIMALS; ANTIGENS, CD26; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASES; ENZYME INHIBITORS; HUMANS;

EID: 4544232468     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.9.1091     Document Type: Review

References (98)

1. AHRÉN B, SIMONSSON E, LARSSON H et al.: Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in Type 2 diabetes. Diabetes Care (2002) 25:869-975.
2. AHRÉN B, LANDIN-OLSSON M, JANSSON PA, SVENSSON M, HOLMES D, SCHWEIZER A: Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduced glucagon levels in Type 2 diabetes. J. Clin. Endocrinol. Metab. (2004) 89:2078-2084.
3. ØRSKOV C, HOLST JJ, KNUHTSEN S, BALDISERRA FG, POULSEN SS, NIELSEN OV: Glucagon-like peptides GLP-1 and GLP-2, predicted products of the proglucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology (1986) 119:1476-1475.
4. MOJSOV S, WEIR GC, HABENER JF: Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J. Clin. Invest. (1987). 79:616-619.
5. HOLST JJ, ØRSKOV C, NIELSEN OV, SCHWARTZ TW: Truncated glucagon-like peptide 1, an insulin-releasing hormone from the distal gut. FEBS Lett. (1987) 211:169-174.
6. ØRSKOV C, HOLST JJ, NIELSEN OV: Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology (1988) 123:2009-2013.
7. FRIDOLF T, BOTTCHER G, SUNDLER F, AHRÉN B: GLP-1 and GLP-1(7-36) amide: influences on basal and stimulated insulin and glucagon secretion in the mouse. Pancreas (1991) 6:208-215.
8. HOLST JJ: Therapy of Type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab. Res. Rev. (2002) 18:430-441.
9. GUTNIAK M, ØRSKOV C, HOLST JJ, AHRÉN B, EFENDIC S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. (1992) 326:1316-1322.
10. NATHAN DM, SCHREIBER E, FOGEL H, MOJSOV S, HABENER JF: Insulinotropic action of glucagonlike peptide-I (7-37) in diabetic and nondiabetic subjects. Diabetes Care (1992) 15:270-276.
11. NAUCK MA, KLEINE N, ØRSKOV C, HOLST JJ, WILLMS B, CREUTZFELDT C: Normalization of fasting hyperglycemia by exogenous GLP-1 (7-36 amide) in Type 2 diabetic patients. Diabetologia (1993) 36:741-744.
12. RACHMAN J, GRIBBLE FM, BARROW BA, LEVY JC, BUCHANAN KD, TURNER RC: Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1/7-36) amide in patients with NIDDM. Diabetes (1996) 45:1524-1530.
13. LARSEN J, HYLLEBERG B, NG K, DAMSBO P: Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in Type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care (2001) 24:1416-1421.
14. NAUCK MA, SAUERWALD A, RITZEL R, HOLST JJ, SCHMIEGEL W: Influence of glucagon-like peptide 1 on fasting glycemia in Type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care (1998) 21:1925-1931.
15. NAUCK MA, WOLLSCHLÄGER D, WERNER J et al.: Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM-Diabetologia (1996) 39:1546-1553.
16. JUNTTI-BERGGREN L, PIGON J, KARPE F et al.: The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients. Diabetes Care (1996) 19:1200-1206.
17. ZANDER M, MADSBAD S, MADSEN JL, HOLST JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in Type 2 diabetes: a parallel-group study. Lancet (2002) 359:824-830.
18. GUTNIAK MK, LARSSON H, HEIBER SJ, JUNESKANS OT, HOLST JJ, AHRÉN B: Potential therapeutic levels of glucagon-like peptide-1 achieved in humans by a buccal tablet. Diabetes Care (1996) 19:843-848.
19. GUTNIAK MK, LARSSON H, SANDERS SW, JUNESKANS O, HOLST JJ, AHRÉN B: GLP-1 tablet in Type 2 diabetes in fasting and postprandial conditions. Diabetes Care (1997) 20:1874-1879.
20. BUCKLEY DI, LUNDQUIST P: Analysis of the degradation of insulinotropin [GLP-1 (7-37)] in human plasma and production of degradation resistant analogs. Regul. Pept (1992) 40:117 (Abstract).
21. MENTLEIN R, GALLWITZ B, SCHMIDT WE: Dipeptidyl peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. (1993) 214:829-835.
22. DEACON CF, JOHNSEN AH, HOLST JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide which is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. (1995) 80:952-957.
23. DEACON CF, NAUCK MA, TOFT-NIELSEN M-B, PRIDAL L, WILLMS B, HOLST JJ: Both subcutaneously and intravenously administered glucagon-like peptide-1 are rapidly degraded from the amino-acid terminus in Type 2 diabetic patients and in healthy subjects. Diabetes (1995) 44:1126-1131.
24. KIEFFER TJ, McINTOSH CHS, PEDERSON RA: Degradation of glucose-dependent insulinotropic polypeptide (GIP) and truncated glucagon-like peptide 1 (tGLP-1) in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology (1995) 136:3585-3596.
25. DEACON CF, DANIELSEN P, KLARSKOV L, OLESEN M, HOLST JJ: Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes (2001) 50:1588-1597.
26. DEACON CF, HUGHES TE, HOLST JJ: Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide-1 in anesthetized pigs. Diabetes (1998) 47:764-769.
27. MARGUET D, BAGGIO L, KOBAYASHI T et al.: Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. USA (2000) 97:6874-6879.
28. DEACON CF, WAMBERG S, BIE P, HUGHES TE, HOLST JJ: Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J. Endocrinol. (2002) 172:355-362.
29. HOLST JJ, DEACON CF: Inhibition of the activity of dipeptidyl peptidase IV as a treatment for Type 2 diabetes. Diabetes (1998) 47:1663-1670.
30. WEIR GC, MOJSOV S, HENDRICK GK, HABENER JF: Glucagonlike peptide I (7-37) actions on endocrine pancreas. Diabetes (1989) 38:338-342.
31. NAGAKURA T, YASUDA N, YAMAZAKI K et al.: Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochem. Biophys. Res. Commun. (2001) 284:501-506.
32. PEDERSON RA, WHITE HA, SCHLENZIG D, PAULY RP, MCINTOSH CH, DEMUTH HU: Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes (1998) 47:1253-1258.
33. BALKAN B, KWASNIK L, MISERENDINO R, HOLST JJ, LI X: Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia (1999) 42:1324-1331.
34. AHRÉN B, HOLST JJ, MARTENSSON H, BALKAN B: Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur. J. Pharmacol. (2000) 404:239-245.
35. POSPISILIK JA, STAFFORD SG, DEMUTH HU et al.: Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/09 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia and β-cell responsiveness in VDF (fa/fa) Zucker rats. Diabetes (2002) 51:943-950.
36. SUDRE B, BROQUA P, WHITE RB et al.: Chronic Inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes (2002) 51:1461-1469.
37. POSPISILIK JA, STAFFORD SG, DEMUTH HU, McINTOSH CH, PEDERSON RA: Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. Diabetes (2002) 51:2677-2683.
38. POSPISILIK JA, MARTIN J, DOTY T et al.: Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes (2003) 52:741-750.
39. REIMER MK, HOLST JJ, AHRÉN B: Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur. J. Endocrinol. (2002) 146:717-727.
40. AHRÉN B, GOMIS R, STANDL E, MILLS D, SCHWEIZER A: Prolonged efficacy of LAF237 in patients with Type 2 diabetes (T2DM) inadequately controlled with metformin. 64th Scientific Sessions of the American Diabetes Association. Orlando, USA (2004) Late-breaking 7-LB (Abstract).
41. CONARELLO SL, LI Z, RONAN J et al.: Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc. Natl. Acad. Sci. USA (2003) 100:6825-6830.
42. YASUDA N, NAGAKURA T, YAMAZAKI K, INOUE T, TANAKA I: Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats. Life Sci. (2002) 71:227-238.
43. PRATLEY R, GALBREATH E: Twelve-week monotherapy with the DPP-4 inhibitor, LAF237 improves glycemic control in patients with Type 2 diabetes (T2DM). Diabetes (2004) 53(Suppl. 2):A83, 355-OR (Abstract).
44. AHRÉN B, GOMIS R, MILLS D, SCHWEIZER A: The DPP-4 inhibitor, LAF237, improves glycemic control in patients with Type 2 diabetes (T2DM) inadequately treated with metformin. Diabetes (2004) 53(Suppl. 2)A83, 354-OR (Abstract).
45. FESTA A, D'AGOSTINO R Jr, HANLEY AJ, KARTER AJ, SAAD MF, HAFFNER SM: Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes (2004) 53:1549-1555.
46. CHIASSON JL, JOSSE RG, GOMIS R, HANEFELD M, KARASIK A, LAAKSO M: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA (2003) 290:486-494.
47. LAMBEIR A-M, DURINX C, SCHARPÉ S, DE MEESTER I: Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPPIV. Crit. Rev. Clin. Lab. Sci. (2003) 40:209-294.
48. ABBOTT CA, YU DM, WOOLLATT E, SUTHERLAND GR, McCAUGHAN GW, GORRELL MD: Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur. J. Biochem. (2000) 267:6140-6150.
49. OLSEN C, WAGTMANN N: Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV. Gene (2002) 299:185-193.
50. LEITING B, NICHOLS E, BIFTU T et al.: Inhibition of dipeptidyl peptidase IV does not attenuate T cell activation in vitro. Diabetes (2004) 53(Suppl. 2):A2, 6-OR (Abstract).
51. LANKAS G, LEITING B, ROY RS et al.: Inhibition of DPP8/9 results in toxicity in preclinical species: Potential importance of selective dipeptidyl peptidase IV inhibition for the treatment of Type 2 DM. Diabetes (2004) 53(Suppl. 2):A2, 7-OR (Abstract).
52. MENTLEIN R: Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul. Pept. (1999) 85:9-24.
53. AHRÉN B: Autonomic regulation of islet hormone secretion. Implications for health and disease. Diabetologia (2000) 43:393-410.
54. LAMBEIR AM, DURINX C, PROOST P, VAN DAMME J, SCHARPÉ S, DE MEESTER I: Kinetic study of the processing by dipeptidyl-peptidase IV/ CD26 of neuropeptides involved in pancreatic insulin secretion. FEBS Lett. (2001) 507:327-330.
55. ZHU L, TAMVAKOPOULOS C, XIE D et al.: The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activarting polypeptide-1(1-38). J. Biol. Chem. (2003) 278:22418-22423.
56. FILIPSSON K, REIMER MK, AHRÉN B: The neuropeptide pituitary adenylate cyclase-activating polypeptide and islet function. Diabetes (2001) 50:1959-1969.
57. SCHAFER H, ZHENG J, GUNDLACH F et al.: Pituitary adenylate-cyclase-activating polypeptide stimulates protooncogene expression and activates the AP-1 (c-Fos/c-Jun) transcription factor in ARA-2J pancreatic carcinoma cells. Eur. J. Biochem. (1996) 242:467-476.
58. HASHIMOTO H, KUNUGI A, ARAKAWA N et al.: Possible involvement of a cyclic AMP-dependent mechanism in PACAP-induced proliferation and ERK activation in astrocytes. Biochem. Biophys. Res. Commun. (2003) 311:337-343.
59. DIETRICH JB: Neuropeptides, antagonists and cell proliferation: bombesin as an example. Cell Mol. Biol. (1994) 40:731-746.
60. BHAVE SV, HOFFMAN PL: Phosphatidylinositol 3′-OH kinase and protein kinase A pathways mediate the anti-apoptotic effect of pituitary adenylyl cyclase-activating polypeptide in cultured cerebellar granule neurons: modulation by ethanol. J. Neurochem. (2004) 88:359-369.
61. YAMAMOTO K, HASHIMOTO H, TOMIMOTO S et al.: Overexrpession of PACAP in transgenic mouse pancreatic β-cells enhances insulin secretion and ameliorates streptozotocin-induced diabetes. Diabetes (2003) 82:1155-1162.
62. YADA T, SAKURADA M, FILIPSSON K, KIKUCHI M, AHRÉN B: Intraperitoneal PACAP administration decreases blood glucose in GK rats, and in normal and high-fat diet mice. Ann. NY Acad. Sci. (2000) 921:259-263.
63. MADSBAD S, SCHMITZ O, RANSTAM J, JAKOBSEN G, MATTHEWS DR: Improved glycemic control with no weight increase in patients with Type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog Liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial. Diabetes Care (2004) 27:1335-1342.
64. FINEMAN MS, BICSAK TA, SHEN LZ et al.: Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with Type 2 diabetes. Diabetes Care (2003) 26:2370-2377.
65. DEFRONZO R, RATNER R, HAN J, KIM D, FINEMAN M, BARON A: Effeccs of exenatide (synthetic exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with Type 2 diabetes. 64th Scientific Sessions of the American Diabetes Association. Orlando, USA (2004) Late-breaking 6-LB (Abstract).
66. NAUCK MA, HOMPESCH M, FILIPCZAK R et al.: Liraglutide significantly improves glycemic control and reduces body weight compared with glimepiride as add-on to metformin in Type 2 diabetes. Diabetes (2004) 53(Suppl. 2):A83, 356-OR (Abstract).
67. HANSOTIA T, BAGGIO LL, DELMEIRE D et al.: Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes (2004) 53:1326-1335.
68. NAGAKURA T, YASUDA N, YAMAZAKI K, IKUTA H, TANAKA I: Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition. Metabolism (2003) 52:81-86.
69. YASUDA N, INOUE T, NAGAKURA T et al.: Metformin causes reduction of food intake and body weight gain, and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats. J. Pharmacol. Exp. Ther. (2004) 310(2):614-619.
70. TAKASAKI K, NAKAJIMA T, UENO K, NOMOTO Y, HIGO K: Effects of combination treatment with dipeptidyl peptidase IV inhibitor and sulfonylurea on glucose levels in rats. J. Pharmacol. (2004) 95:291-293.
71. BURKEY BF, LI X, BOLOGNESE L et al.: Combination treatment of a DPP-IV inhibitor NVP-LAF237 with pioglitazone completely normalized glucose tolerance in adult obese Zucker rats. Diabetes (2002) 51(Suppl. 2):A338 (Abstract).
72. WEBER A, KIM D, BECONI M et al.: MK-0431 is a potent, selective dipeptidyl peptidase IV inhibitor for the treatment of Type 2 diabetes. Diabetes (2004) 53(Suppl. 2):A151, 633-P (Abstract).
73. LI Y, HANSOTIA T, YUSTA B, RIS F, HALBAN PA, DRUCKER DJ: Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J. Biol. Chem. (2003) 278:471-478.
74. BOSE AK, MOCANU MM, MENSAH KN, BRAND CL, CARR RD, YELLON DM: GLP-1 protects ischemic and reperfused myocardium via PI3 kinase and p42/p44 MAPK signalling pathways. Diabetes (2004) 53(Suppl. 2):A1, 2-OR (Abstract).
75. VILSBØLL T, KRARUP T, DEACON CF, MADSBAD S, HOLST JJ: Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in Type 2 diabetic patients. Diabetes (2001) 50:609-613.
76. MEIER JJ, NAUCK MA, KRANZ D et al.: Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes (2004) 53:654-662.
77. HERMAN GA, ZHAO P-L, DIETRICH B et al.: The DP-IV inhibitor MK-0431 enhances active GLP-1 and reduces glucose following an OGTT in Type 2 diabetics. Diabetes (2004) 53(Suppl. 2):A82, 353-OR (Abstract).
78. LARSEN MO, ROLIN B, RIBEL U et al.: Valine pyrrolidide preserves intact glucose-dependent insulinotropic peptide and improves abnormal glucose tolerance in minipigs with reduced beta-cell mass. Exp. Diabesity Res. (2003) 4:93-105.
79. NAUCK MA, HEIMESAAT MM, ØRSKOV C, HOLST JJ, EBERT R, CREUTZFELDT W: Preserved incretin activity of glucagon-like peptide 1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with Type II diabetes mellitus. J. Clin. Invest. (1993) 91:301-307.
80. ELAHI D, MCALOON-DYKE M, FUKAGAWA NK et al.: The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul. Pept. (1994) 51:63-74.
81. MENEILLY GS, BRYER-ASH M, ELAHI D: The effect of glyburide on β-cell sensitivity to glucose-dependent insulinotropic polypeptide. Diabetes Care (1993) 16:110-114.
82. LYNN FC, PAMIR N, NG EH, MCINTOSH CH, KIEFFER TJ, PEDERSON RA: Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes (2001) 50:1004-1011.
83. LYNN FC, THOMPSON SA, POSPISILIK JA et al.: A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells. FASEB J. (2003) 17:91-93.
84. TANAKA S, MURAKAMI T, NONAKA N, OHNUKI T, YAMADA M, SUGITA T: Anti-arthritic effects of the novel dipeptidyl peptidase IV inhibitors TMC-2A and TSL-225. Immunopharmacology (1998) 40:21-26.
85. WILLIAMS YN, BABA H, HAYASHI S et al.: Dipeptidyl peptidase IV on activated T cells as a target molecule for therapy of rheumatoid arthritis. Clin. Exp. Immunol. (2003) 131:68-74.
86. JONES B, ADAMS S, MILLER GT, JESSON MI, WATANABE T, WALLNER BP: Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies. Blood (2003) 102:1641-1648.
87. KOROM S, DE MEESTER I, STADLBAUER TH et al.: Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Transplantation (1997) 63:1495-1500.
88. STEINBRECHER A, REINHOLD D, QUIGLEY L et al.: Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo. J. Immunol. (2001) 166:2041-2048.
89. RASMUSSEN H B, BRANNER S, WIBERG FC, WAGTMANN N: Crystal structure of human dipeptidyl peptidase IV/ CD26 in complex with a substrate analog. Nat. Struct. Biol. (2003) 10:19-25.
90. OEFNER C, D'ARCY A, MacSWEENEY A, PIERAU S, GARDINER R, DALE GE: High-resolution structure of human apo dipeptidyl peptidase IV/CD26 and its complex with 1-[([2-[(5-iodopyridin-2-yl)amino]-ethyl]amino)-acetyl]-2-cyano-(S -pyrrolidine. Acta. Crystallogr. D. Biol. Crystallogr. (2003) 59:1206-1212.
91. THOMA R, LOFFLER B, STIHLE M, HUBER W, RUF A, HENNIG M: Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV. Structure (2003) 1:947-959.
92. HUPE-SODMANN K, McGREGOR GP, BRIDENBAUGH R et al.: Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul. Pept. (1995) 58:149-156.
93. GEE NS, BOWES MA, BUCK P, KENNY AJ: An immunoradiometric assay for endopeptidase-24.11 shows it to be a widely distributed enzyme in pig tissues. Biochem. J. (1985) 228:119-126.
94. PLAMBOECK A, HOLST JJ, CARR RD, DEACON CF: Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both involved in regulating the metabolic stability of glucagon-like peptide-1 in vivo. Adv. Exp. Med. Biol. (2002) 524:303-312.
95. OEFNER C, PIERAU S, DALE GE: Ectopeptidases and Type II diabetes. 11th Protein Structure Determination in Industry, Cambridge, UK (2003) T001 (Abstract).
96. ZHANG BB, WOODS JW, LI Z et al.: Chronic inhibition of dipeptidyl peptidase IV increases pancreatic beta cell mass in a murine model of Type 2 diabetes. 64th Scientific Sessions of the American Diabetes Association. Orlando, USA (2004) Late-breaking 58-LB (Abstract).
97. STÖCKEL-MASCHEK A, MRESTANI-KLAUS C, STIEBITZ B, DEMUTH HU, NEUBERT K: Thioxo aminoacid pyrrolidides and thiazolidides: new inhibitors of proline specific peptidases. Biochim Biophys Acta (2000) 1479:15-31.
98. VILLHAUER EB, BRINKMAN JA, NADERI GB et al.: 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem. (2003) 46:2774-2789.